Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · mng-umap@100

MNG589

—

1782c265-0494-5e43-ae93-f5cd6ef1c70d

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
—

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • EPITHELIAL_MESENCHYMAL_TRANSITION+0.436
  • OXIDATIVE_PHOSPHORYLATION+0.416
  • MYOGENESIS+0.367
  • ALLOGRAFT_REJECTION+0.320
  • COAGULATION+0.304
  • CHOLESTEROL_HOMEOSTASIS+0.289
  • ANGIOGENESIS+0.281
  • UV_RESPONSE_UP+0.273
  • MYC_TARGETS_V2+0.228
  • P53_PATHWAY+0.228

Top 10 suppressed

  • G2M_CHECKPOINT-0.424
  • PROTEIN_SECRETION-0.401
  • E2F_TARGETS-0.366
  • MITOTIC_SPINDLE-0.342
  • INTERFERON_ALPHA_RESPONSE-0.245
  • UV_RESPONSE_DN-0.177
  • TGF_BETA_SIGNALING-0.165
  • INTERFERON_GAMMA_RESPONSE-0.141
  • SPERMATOGENESIS-0.137
  • ANDROGEN_RESPONSE-0.119

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

10 twins match this tumor's tissue · 0 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1TCGA-XF-A9SU-01A-31R-A39I-07
bladder-landscape@3
——0.845
2MNG482
mng-umap@100
——0.839
309f758e5-6be1-4f29-ac92-869d92f8fbcf
melanoma-umap@29
——0.836
4MNG1090
mng-umap@100
——0.835
5TCGA-OL-A66L-01A-12R-A31O-07
breast-umap@18
—B0.817
6TCGA-AC-A3QP-01A-11R-A22U-07
breast-umap@18
—B0.799
7TCGA-AN-A0FT-01A-11R-A034-07
breast-umap@18
—B0.796
8TCGA-85-A4JC-01A-11R-A24Z-07
lung-landscapes@6
—cohortSQ10.787
99a4f9e4a-dc97-4f8d-9075-537b62fb98d3
melanoma-umap@29
——0.785
10MNG413
mng-umap@100
——0.781

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 34 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
EPITHELIAL_MESENCHYMAL_TRANSITION0.436Inavolisib— uncovered
OXIDATIVE_PHOSPHORYLATION0.416Remibrutinib— uncovered
MYOGENESIS0.367Inavolisib— uncovered
ALLOGRAFT_REJECTION0.320Idelalisib— uncovered
COAGULATION0.304Binimetinib— uncovered
CHOLESTEROL_HOMEOSTASIS0.289Remibrutinib— uncovered
ANGIOGENESIS0.281Remibrutinib— uncovered
UV_RESPONSE_UP0.273Idelalisib— uncovered
MYC_TARGETS_V20.228Idelalisib— uncovered
P53_PATHWAY0.228Idelalisib— uncovered
XENOBIOTIC_METABOLISM0.227Inavolisib— uncovered
FATTY_ACID_METABOLISM0.211Inavolisib— uncovered
KRAS_SIGNALING_DN0.199Remibrutinib— uncovered
ADIPOGENESIS0.176Inavolisib— uncovered
IL2_STAT5_SIGNALING0.175Idelalisib— uncovered
TNFA_SIGNALING_VIA_NFKB0.175Inavolisib— uncovered
PANCREAS_BETA_CELLS0.174Cobimetinib— uncovered
APICAL_JUNCTION0.159Inavolisib— uncovered
REACTIVE_OXYGEN_SPECIES_PATHWAY0.138Inavolisib— uncovered
APOPTOSIS0.129Idelalisib— uncovered